U.S. markets close in 5 hours 49 minutes

  • S&P 500

    3,898.47
    -32.86 (-0.84%)
     

  • Dow 30

    31,385.06
    -227.96 (-0.72%)
     

  • Nasdaq

    13,788.97
    -176.52 (-1.26%)
     

  • Russell 2000

    2,236.31
    -19.80 (-0.88%)
     

  • Crude Oil

    61.19
    +0.05 (+0.08%)
     

  • Gold

    1,773.30
    +0.50 (+0.03%)
     

  • Silver

    27.16
    -0.16 (-0.59%)
     

  • EUR/USD

    1.2074
    +0.0028 (+0.23%)
     

  • 10-Yr Bond

    1.3130
    +0.0120 (+0.92%)
     

  • GBP/USD

    1.3946
    +0.0082 (+0.59%)
     

  • USD/JPY

    105.8300
    -0.0410 (-0.04%)
     

  • BTC-USD

    51,978.21
    +807.07 (+1.58%)
     

  • CMC Crypto 200

    1,060.75
    +0.98 (+0.09%)
     

  • FTSE 100

    6,623.64
    -87.26 (-1.30%)
     

  • Nikkei 225

    30,236.09
    -56.10 (-0.19%)
     
JOBS:

Another 861,00 Americans filed new unemployment claims for week ended Feb. 13

The number of filings unexpectedly surged above 800,000

Global Automotive Health, Wellness and Wellbeing Markets Report 2020-2025: Smart Cars with HWW Features that Complement Advanced Safety Systems are Set to Become New Points of Healthcare Delivery

·7 min read

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- The "Industry Convergence and Innovative Technologies Positioning Cars as Vehicles of Health, Global, 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

This research service analyses and provides forecasts for HWW features in the automotive industry. It identifies growth opportunities and strategies for automotive OEMs. Further, it offers insights through a comparative analysis of key global OEMs' strategies to include health monitoring features - whether built-in, brought-in, or cloud-enabled. This research also presents profiles of key HWW players. It concludes with an actionable set of recommendations.

The automotive industry, already reeling under a challenging 2019, has been dealt a further blow by Coronavirus (COVID-19) , since the demand for durable goods such as new passenger cars, light commercial vehicles (LCVs), and allied mobility activities will halt for the time being and later due to a change in purchasing priority. Amidst this socio-economic calamity, there are some business verticals that are well positioned to crest a wave of new opportunities thrown up by the COVID storm.

In the process, the analyst expects the Health, Wellness, & Wellbeing (HWW) component in the Automotive Industry to surge in order to reposition focus areas and charter new growth paradigms. Healthcare digitisation, emergence of mHealth apps, and their integration in the car for clean and pathogen-free interiors, driver monitoring, and diagnosis are expected to gain strong footholds in the industry.

The entire research report has been analysed based on 3 possible routes of solution delivery by automotive companies can take: built-in, brought-in, and beamed-in.

The built-in route encompasses HWW features enabled through hardware like, for instance, sensors that are factory fit into vehicles by auto manufacturers. Brought-in HWW features will happen through devices brought in by drivers and passengers, such as smartphones, smart glasses, smart headsets, and smart watches. Finally, beamed-in solutions will basically be cloud-based and will be enabled in vehicles via secure virtual technology platforms from secured private/public databases.

In response to the recent COVID pandemic, a few automakers have already started work on redesigning their cars. Similar trends are playing out in the aftermarket with a focus on innovative products that aid in-vehicle air purification. For example, Jaguar Land Rover (JLR) has been working on advanced ultraviolet (UV) ray technology that can kill germs while Geely has already launched an SUV equipped with an N95 air-filtration system capable of purifying the air of bacteria and viruses.

Meanwhile, Droom, the aftermarket player is offering an antimicrobial surface protection shield for cars and two-wheelers which will be effective against SARS and other droplet-based viruses. Another player Gr?nliteT utilises industry-leading UV technology and integrated smart sensors to detect when a vehicle is unoccupied and automatically emit a dose of UV-C light that disinfects the vehicle.

It is quite evident that there are opportunities for the automotive sector to connect to the medical world, enhance the user experience, and enhance the daily life of their customers. In order to integrate medical features in the automotive environment, it is of great importance the legislative landscape is known, which on the flipside is also a challenge. Declaring the vehicle as a medical device might require the whole vehicle to be certified through non-vehicle traditional channels like FDA. Then there is also the bigger problem of liability and ambiguities in privacy law. These, coupled with the mix of stakeholders involved, highlight the high probability of failure and high risk of conflicts and liability concerns.

However, with developments in the market, we expect the regulations to also evolve. With the right set of partners, we can expect HWW to grow as a separate, dedicated theme (just like safety and convenience) by 2025.

Overall, the main aspects covered as part of this study are as listed below:

  • Current implemented HWW solutions and the main challenges/pain points faced by automakers

  • Key drivers that will underpin market growth in the short to medium term

  • Future HWW capabilities customers would want to have; and the one that is the most relevant for them

  • Scope of solutions offered by different stakeholders - OEMs, technology providers, and Tier 1 & 2 suppliers - as well as understanding the shift towards the digital health marketplace

  • Current technology stakeholder ecosystem, opportunities for OEMs for partnerships in the future, and the areas they should focus on

  • Changed landscape as a consequence of COVID-19; automakers' preparedness for the same, changes in their strategies, and the expected future roadmap

  • Autonomous cars and the changes they will bring about in the in-cars HWW landscape

Key Topics Covered:

1. Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?

  • The Strategic Imperative

  • The Impact of Top 3 Star Imperative on the Automotive HWW Industry

  • Growth Opportunities Fuel The Growth Pipeline Engine

2. Growth Opportunity Analysis

  • Automotive HWW Market Overview

  • HWW Segmentation in the Automotive Industry

  • Key Competitors in the Automotive HWW Market

  • Key Growth Metrics

  • Growth Drivers for the Automotive HWW Market

  • Growth Restraints for the Automotive HWW Market

  • Forecast Assumptions

  • Total Addressable Market Forecast - Scenario 1 (Low Penetration Rate)

  • Total Addressable Market Forecast - Scenario 2 (Medium Penetration Rate)

  • Total Addressable Market Forecast - Scenario 3 (High Penetration Rate)

  • Addressable Market Forecast Discussion

  • Stakeholder Comparative Analysis - Automotive OEMs

  • Stakeholder Comparative Analysis - Tier 1 & 2 Suppliers

  • Stakeholder Comparative Analysis - Technology Start-ups

3. Market Analysis

  • Key Findings

  • Ageing Population offers a Sizeable Opportunity and Need for Healthcare Provision

  • Air Quality Control in Cars - An Important Feature

  • Car being an Integral Part of People's Lives offers Ample Opportunity for In-Car HWW Services

  • Technology Shifts in Healthcare

  • Technology Shifts in Cars

  • HWW in Vehicles - from Provision of Care to a Lifestyle Avatar

  • Mapping of In-Car and Healthcare Features

  • Evolution of In-Car HWW Services

  • Automotive HWW Ecosystem

  • In-Car Health and Wellness Monitoring Concepts

  • HWW Segmentation in the Automotive Industry

  • Built-in Automotive HWW Features

  • Automakers Focussing on Biometric and Sensing Technologies

  • Brought-in and Beamed-in Technologies

  • Brought-in Technologies which can be leveraged for HWW in Vehicles

  • Increasing Focus on HWW Features driven by Connected Automotive + Wearables Technologies

  • Beamed-in Technologies which can be leveraged for HWW in Vehicles

  • Connected Car Platform and Solution Providers for Future HWW Capabilities

  • Innovation Key to Growth for HWW Services

  • Example Future Driver Use Cases of HWW in Cars

4. Competitor Landscape Analysis

  • Competitor Landscape - OEM: Ford

  • Competitor Landscape - OEM: Mercedes Benz

  • Competitor Landscape - OEM: Volvo

  • Competitor Landscape - OEM: JLR

  • Competitor Landscape - OEM: Honda

  • Competitor Landscape - OEM: Hyundai/Kia

  • Competitor Landscape - Tier-1 Supplier: Valeo

  • Competitor Landscape - Tier-1 Supplier: Bosch

  • Competitor Landscape - Tier-1 Supplier: Continental

  • Competitor Landscape - Tier-1 Supplier: Comfort Motion Global

  • Competitor Landscape - Tier-1 Supplier: Yanfeng

  • Competitor Landscape - Tech Start-ups: Adam Cogtec

  • Competitor Landscape - Tech Start-ups: Vigo

  • Competitor Landscape - Tech Start-ups: Freerlogic

  • Competitor Landscape - Tech Start-ups: Cerence

  • Competitor Landscape - Tech Start-ups: binah.ai

  • Competitor Landscape - Tech Start-ups: Affectiva

5. Challenges Surrounding the Implementation of Automotive HWW Solutions

  • Overview of Regulatory Landscape for the Uptake of Connected Car HWW Services

  • Liabilities and Concerns for the Development of Connected Car HWW Services

  • Mapping OEM Liabilities towards HWW Vehicle Technologies

6. Implications of COVID-19 on the HWW Industry (Short, Mid, and Long Terms)

  • COVID-19 to Redesign Cars and Mobility

  • Consumers' Car Purchase Considerations Shifting towards Health Configurations

  • COVID-19 Impact: OEM Mitigation Strategies & HWW

7. Conclusions and Future Outlook

  • Potential HWW Applications and Services, 2025-2035

  • Data Monetisation Opportunities for OEMs from Various Data Points Available

  • Impact on HWW Features with Increasing Vehicle Autonomy

  • Driverless Car for Healthcare

  • Critical Solution Success Factors in Health & Wellness

8. Growth Opportunities

  • Growth Opportunity: HWW Features in Cars to Accelerate driven by the Pandemic and Consumer Demand, 2020

9. Next Steps

Companies Mentioned

  • Adam Cogtec

  • Affectiva

  • binah.ai

  • Bosch

  • Cerence

  • Comfort Motion Global

  • Continental

  • Droom

  • Ford

  • Freerlogic

  • Gr?nliteT

  • Honda

  • Hyundai/Kia

  • Jaguar

  • JLR

  • Mercedes Benz

  • Valeo

  • Vigo

  • Volvo

  • Yanfeng

For more information about this report visit https://www.researchandmarkets.com/r/r8dpe0



Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/global-automotive-health-wellness-and-wellbeing-markets-report-2020-2025-smart-cars-with-hww-features-that-complement-advanced-safety-systems-are-set-to-become-new-points-of-healthcare-delivery-301230790.html

SOURCE Research and Markets

Latest Stories

  • Palantir Is a Buy! Palantir Is a Sell! Why Wall Street Is Split.

    It's a weird development that vividly demonstrates just how split Wall Street is on the prospects for the data-analytics company.

  • Biden’s $2 Trillion Green Plan Could Send This Stock Soaring

    One massive project changed the face of America in 1935. But now, Biden’s set to continue this plan 85 years later, creating sweeping changes across the nation

  • Retirement Balances Hit Records, So Do Ranks Of Fidelity 401(k) And IRA Millionaires

    Millions of retirement savings accounts hit record balances in the fourth quarter. The number of IRA and 401(k) millionaires also set records.

  • AMC Shares Spike Again, This Time on Months-Old Speculation

    (Bloomberg) -- AMC Entertainment Inc., whose shares are a favorite of Reddit-inspired day traders, jumped on Thursday after the publication of a French translation of a months-old report speculating Amazon.com Inc. would buy the world’s biggest chain of movie theaters.The article in Forbes France is dated today, but notes at the bottom it’s a translation of a Forbes US piece. The American version was published last May. Both versions note the Amazon acquisition idea is “pure speculation,” but cite reasons it would make sense, including the financial struggles of AMC and Amazon’s successful content arm Prime Video. Amazon and AMC didn’t immediately respond to a request for comment.AMC shares jumped as much as 19% in premarket trading and were up 9% to $6.05 at 9:33 a.m. in New York. The stock had gained 162% this year through Wednesday’s close after getting swept up in the Reddit-board mania that sent stocks such as GameStop Corp. soaring. It also got a boost after it said it raised $917 million in new funds, which will allow it to get through the next six months of the pandemic and avoid filing for bankruptcy.(Updates with Amazon and AMC no comment in second paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Warren Buffett's Berkshire Cuts Apple Stake And Buys These Drugmaker, Telecom Stocks Instead

    Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) cut its positions in Apple Inc (NASDAQ: AAPL) and piled on stocks of drug, telecom, and oil companies in the latest quarter, according to filings made with the U.S. Securities and Exchange Commission. What Happened: The Warren Buffett-led company shed its Apple stake by 6% to 887 million shares in the quarter, but at the same time has upped its investments in AbbVie Inc (NYSE: ABBV) by 20%, Bristol-Myers Squibb Company (NYSE: BMY) by 11%, and Merck & Co, Inc (NYSE: MRK) by 28%. The conglomerate increased its exposure to T-Mobile US, Inc (NASDAQ: TMUS) by 1.36% to 5.2 million shares and also added 146.7 million shares of Verizon Communications Inc (NYSE: VZ). See Also: Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic Berkshire picked up a fresh stake of 48.5 million Chevron Corporation (NYSE: CVX) shares and increased its investment in The Kroger Co (NYSE: KR) by 34%. Other changes include a 59% cut in exposure to Wells Fargo & Co (NYSE: WFC) and a 28% cut in Suncor Energy Inc (NYSE: SU) stake. Why It Matters: Apple is still the largest single investment in Berkshire’s portfolio, as of the latest 13F filing, and the investment is worth about $120 billion. See Also: Warren Buffett Called Bitcoin 'Rat Poison' — Now It's Closing In On Berkshire Hathaway's Valuation Apple shares closed nearly 1.6% lower at $133.19 on Tuesday and fell another 0.41% in the after-hours session. In the after-hours trading on Tuesday — AbbVie shares were up 0.42% at $104.64. Bristol-Myers shares rose 0.34% to $59.60. T-Mobile shares rose 0.86% to $123.05. Verizon shares shot up 3.05% to $55.80 in the after-hours trading, while Chevron shares rose 2.54% to $95.50. Wells Fargo shares were down 0.11% in the after-hours. Kroger and Suncor shares remained largely unchanged. Price Action: Berkshire Hathaway Class A shares closed 1.23% higher at $369,333. The company’s class B shares closed 1.15% higher at $245.28 and fell 0.11% in the after-hours session. Photo by Fortune Live Media on Flickr See more from BenzingaClick here for options trades from BenzingaTikTok In Negotiations To Go Public On NYSE: Chinese MediaWhy Apple Getting Increasingly Serious About Making Cars? 'Transportation' Dwarfs 'Smartphone' Market, Says Munster© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • How to Avoid Paying Taxes on Your Social Security

    Social Security benefits can provide an additional income stream in retirement alongside withdrawals from a 401(k), individual retirement account or brokerage account. Part of shaping a retirement plan around Social Security income means planning ahead for taxes. Social Security benefits … Continue reading → The post How to Avoid Paying Taxes on Your Social Security appeared first on SmartAsset Blog.

  • If you want to get rich with marijuana stocks, you need to know the crucial difference between U.S. and Canadian companies

    U.S. companies are overlooked by many investors. But any state and federal legalization favors them over Canadian rivals, fund managers say.

  • When to expect your next stimulus check? These dates are key to the timing

    Congress is burning rubber to get a bill to President Biden in a race against time.

  • We were ‘dangerously close’ to collapse of ‘entire system,’ says Interactive Brokers founder ahead of GameStop hearing

    Thomas Peterffy, founder and chairman of Interactive Brokers Group Inc., on Wednesday explained the dire situation in which the market stood in late January as individual investors on social-media platforms were banding together to send a handful of heavily shorted stocks dramatically higher.

  • Stocks To Watch: Square Among 7 Stocks Expecting Up To 128% Growth In 2021

    What are the fastest-growing stocks to watch in 2021? Here's a list featuring DocuSign, Square, Daqo and four other stocks expecting up to 128% growth.

  • J.P. Morgan Says These 3 Gold Stocks Could Surge 40% (Or More)

    Let’s talk about gold. The precious metal is the traditional safe haven investment, backed by its use – starting 5,000 years ago – as a reliable store of value. Investors looking to protect their portfolio and secure their wealth traditionally bought heavily into gold, and the price of gold has sometimes been used as a proxy (albeit an inverse one) for general economic health. In a recent report, investment firm J.P. Morgan took a long look at the state of the gold industry – specifically, the gold mining industry. Analyst Tyler Langton points out an underlying paradox in two basic facts about gold mines. “Over time, in a commodity business, the lowest cost producers with the longest life assets tend to be the relative winners… Gold mines, when compared to base metals, typically have much shorter mines (sic) lives, and the gold miners have to focus on replacing reserves to maintain levels of production,” Langton noted. At first glance, Langton’s paradox may seem to point away from heavy investments in gold mines. After all, these are high-risk commodity producers. But current times are actually pretty good for gold miners. Prices are elevated compared to recent years; the metal is running just under $1,800 per ounce now, but it peaked above $2,000 in August of last year, at the height of the corona shutdowns, and it was as low as $1,200 just 18 months ago. The current high prices bode well for producers. Langton states his belief that there is support for current prices, with gold and gold mines being seen as a hedge against ‘macro uncertainty.’ He believes that the main sources of support will be found in “real interest rates remaining lower for longer and COVID-19 related stimulus measures continuing to expand central bank balance sheets.” With this in the background, Langton and his colleagues have begun selecting the gold mining stocks they see as winners in the current environment. Unsurprisingly, they like the companies that show discipline on M&A activity, a focus on free cash flow, and solid returns to shareholders. Using the TipRanks database, we’ve pulled up the details on several of their recent picks. Are they as good as gold? The analysts seem to think so; all are Buy-rated and potentially offer significant upside. Let’s dig in. Kinross Gold Corporation (KGC) First up, Kinross Gold, is a mid-cap company– valued at $8.6 billion – with active mining operations in the US, Brazil, West Africa, and Russia. Taken together, these operations have proven and probable gold reserves of 29.9 million ounces. The company is guiding toward 2.4 million ounces in total production for 2021, rising to 2.9 million ounces by 2023. The company’s profitability can be seen by cost of sales per ounce, at $790, and the all-in sustaining cost, at $1,025 per ounce. With gold currently selling at $1,782 on the commodity exchanges, Kinross’s near-term success is clear. Two sets of statistics highlight Kinross’ profitability. First, the company’s recent record of quarterly results shows steadily rising revenues and earnings. Aside from a dip in 1Q20, at the start of the corona crisis, Kinross’ revenues have been gaining steadily since the start of 2019 – and even in 2020, every quarter showed a year-over-year increase. After 7 years without dividend payments, Kinross used its strong performance in recent months to restore the company dividend. Payments are still made irregularly, but since announcing in September 2020 that the dividend would be reinstated, two payments have been made and a third has been announced for March of this year. Each payment has been for 3 cents per share, which translates to a modest yield of 1.6%. The key point here is not strength of the yield, but rather, the confidence that management has displayed in the near- to mid-term by restarted dividend payments. Based on current production projections, the payments are expected to continue until 2023. Tyler Langton, in his notes on Kinross, comes to a bullish conclusion: “Given its expected growth projects and pipeline of additional projects, we think Kinross will be able to maintain average annual production of 2.5mm oz. over the next decade. The company has an attractive cost profile, and we expect costs to decrease over the next several years. The company should also generate attractive strong levels of FCF at current gold prices, and we expect Kinross to direct this cash toward internal growth projects and its dividend.” In line with these comments, he selects Kinross as JPM’s ‘top pick in the gold sector,’ and rates the stock as Overweight (i.e., a Buy). His $11 price target suggests a 61% upside potential in the coming year. (To watch Langton’s track record, click here) Kinross gets a Strong Buy recommendation from the analyst consensus, based on a 6 to 2 split between the Buy and Hold reviews. Wall Street’s analysts have set an average price target of $11.25, slightly more bullish than Langton’s, and implying a one-year upside of 64% from the current trading price of $6.85. (See KGC stock analysis on TipRanks) SSR Mining, Inc. (SSRM) Moving up north to Canada, we now take a look at Vancouver-based SSR Mining. This is another mid-cap mining company, producing gold and silver in quantity through four active mines in Canada, the US, Argentina, and Turkey. The Canadian, US, and Turkish operations produce primarily gold, while the Puna operation is Argentina’s largest silver mine. Although SSR missed on both the top- and bottom-line estimates in its latest quarterly report, for the 2020 full-year production numbers, the company met the previously set guidance. Gold production for the year hit 643,000 ounces, with 31% of that total coming in the fourth quarter. Silver production at the Puna mine reached 5.6 million ounces, beating the guidance figures. Fourth quarter production was 39% of the total. Last November, the company announced that it will be initiating a dividend policy starting in 1Q21. The ‘base dividend’ will be set at 5 cents per share, or a 1% yield; as with KGC above, the key point is not whether the dividend is high or low, but that management is starting to pay it out – a sign of confidence in the future. Langton bases his assessment of SSRM on its strong free cash flow forecast, writing, “At current gold forward prices, we estimate that SSR will generate close to $400mm of FCF in 2021 and around $500mm per year from 2022-2024. Furthermore, starting from a 2021 base, we forecast that SSR would generate cumulative FCF from 2021- 2025 of US$2.3bn, or roughly 59% of its current market cap…” In line with his comments, Langton puts an Overweight (i.e. Buy) rating on the stock, along with a $24 price target that indicates a 60% upside for the next 12 months. (To watch Langton’s track record, click here) There are 8 recent reviews on SSRM shares – and every single one of them is a Buy, making the Strong Buy analyst consensus rating here unanimous. The stock is selling for $15.25, and its robust $28.78 average price target suggests a high 89% one-year upside. (See SSRM stock analysis on TipRanks) Newmont Mining (NEM) Last on the list, Newmont, is the world’s largest gold miner, boasting a $45.78 billion market cap, and active production in a variety of metals, including gold, silver, copper, zinc, and lead. The company has assets – both operations and prospects – in North and South America, Africa, and Australia, and is the only gold miner listed on the S&P 500. With that last detail in mind, it’s worth noting that NEM shares are up 29% in the last 12 months – more than the S&P’s gain of 16% over the same period. In 3Q20, the company showed $3.12 billion in revenue. While this missed the forecast, it did improve on the prior year’s Q3 by 5.4%. The Q3 results were also a company record, with a free cash flow of $1.3 billion. Results below expectations were a common pattern for the company’s 2020 performance in Q1 and Q2, as well. The corona crisis depressed results, but even the depressed results were up year-over-year. Newmont has an active capital return program for shareholders. Since the beginning of 2019, the company has used both dividends and share repurchases to return capital to stakeholders, to the tune of $2.7 billion. This past January, Newmont announced a $1 billion continuation of the share repurchases. Looking ahead to 2021, the company has also announced a new dividend framework, setting the base payment at $1 per share annualized, and reiterated its commitment to capital return. JPM’s Michael Glick led the note on Newmont, starting out by acknowledging the company’s strong production: “We are forecasting NEM’s attributable gold production to remain relatively steady over the 2021-2025 time frame at around 6.5-6.7mm oz…” Of the company’s mid-term production prospects Glick went on to say, “In terms of production, the ongoing expansion at Tanami should deliver incremental production and lower cash costs starting in 2023. Additionally, we expect Newmont to approve its Ahafo North and Yanacocha Sulfides projects this year, which should bring on incremental production for the company after the projects’ roughly three-year development time-line.” Glick likes Newmont’s FCF and production numbers, using them to back his Overweight (Buy) rating. His $83 price target implies an upside of 46% for the months ahead. (To watch Glick’s track record, click here) Newmont, for all its strength, still gets a Moderate Buy rating from the analyst consensus. This is based on 8 reviews, including 5 Buys and 3 Holds. The average price target is $74.97, suggesting room for 31% growth from the current trading price of $56.99. (See NEM stock analysis on TipRanks) To find good ideas for gold stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Warren Buffett is right to bet big on 5G: former Cisco CEO

    Former Cisco CEO John Chambers weighs in on Warren Buffett's big bets on 5G.

  • Dow Jones Futures Fall, Signal Stock Market Losses: Tesla Cuts Prices Again; Twilio, Tilray Key Earnings Movers

    Futures signal fresh losses. Tesla cut prices again. Walmart, Twilio and Tilray are key earnings movers.

  • What Rate of Return Should I Expect on My 401(k)?

    There's no one number. Pinpoint what you’ll need in retirement and your time frame until that day, and derive what to expect from your 401(k) from that.

  • AbbVie Posts A Massive Growth Quarter — Is It Time To Add AbbVie Stock?

    AbbVie stock was within a buy zone in mid-February after the company topped fourth-quarter views and issued upbeat 2021 guidance. The company also has the option to buy Cypris Medical.

  • The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’

    Today, we’re looking at two small-cap biotech firms whose stocks have struck a rut. Each company has hit a recent clinical setback that sent the share price falling, erasing previous gains and sending it back down to low levels. Setbacks of this sort are not uncommon in the biotech industry, and in fact highlight the risk and speculative nature of the industry. So what should investors do, when a stock collapses? Is this a matter of poor fundamentals? And has the stock’s price found its low point yet? That’s where the Wall Street pros come in. Noting that each is set to take back off on an upward trajectory, some 5-star analysts see an attractive entry point for both. Using TipRanks’ database, we found out that these two tickers have earned Moderate or Strong Buy consensus ratings from the analyst community, and boast strong upside potential. Cortexyme, Inc. (CRTX) The first beaten-down name we're looking at is Cortexyme, a clinical-stage biopharma company focused on degenerative diseases, especially Alzheimer’s. The company's lead candidate is COR388, also called atuzaginstat. Atuzaginstat is currently under investigation in the GAIN trial, a study of its efficacy against Alzheimer’s disease. The trial is fully enrolled, with 643 patients, and the company was moving toward an open label enrollment (OLE) section of the Phase 2/3 study. During a routine regulatory update, Cortexyme announced that the OLE phase would be halted, although the primary GAIN study will continue, with results due to be released in Q4 2021. The announcement of the partial halt triggered a 35% drop in share price. The partial hold was prompted by adverse events on the liver during the atuzaginstat trial. The hepatic symptoms were reversible and showed no long-term lasting effects. The FDA reviewed these records, and in collaboration with Cortexyme the decision was made to hold the OLE while continuing with GAIN. This decision allows the main thrust of the program to continue, while working out a new protocol for the OLE. The purpose of the OLE is to test long-term efficacy and tolerability of the drug. In a review of Cortexyme after the announcement, HC Wainwright’s 5-star analyst Andrew Fein noted, “Cortexyme's announcement of a partial clinical hold on the OLE study of atuzaginstat is disappointing, but the reversible nature of the liver toxicity might provide some ray of hope for Cortexyme. We believe that the pivotal trial's continuation suggests that the drug-induced liver injury might not be severe enough to halt the program.” Turning to the near-term, Fein adds, “Continuation of the GAIN trial is encouraging despite the partial hold on OLE. It suggests that FDA plans to wait for the additional data from the pivotal trial before coming to any conclusion. Management shared that nearly one-third of the GAIN patients have completed the study and way past the 12-week time point, suggesting that they are out of risk.” To this end, Fein rates CRTX a Buy, and his $76 price target indicates confidence in a 147% growth potential. (To watch Fein’s track record, click here) Overall, Cortexyme has a Moderate Buy rating from the analyst consensus, with 6 recent reviews breaking down 4 to 1 to 1, Buy-Hold-Sell. The stock’s $83.60 average price target suggests that Wall Street sees a high potential here, on the order of ~170% upside from the trading price of $30.74. (See CRTX stock analysis on TipRanks) Immunovant (IMVT) Next up is Immunovant, a clinical stage biopharmaceutical research firm, focused on developing treatments for patients with autoimmune disorders, a class of diseases in which the immune system attacks the patient’s own body. The firm’s lead drug candidate, IMVT-1401, is undergoing trials as a treatment for thyroid eye disease, myasthenia gravis, and warm autoimmune hemolytic anemia. The drug described as “a novel, fully human anti-FcRn monoclonal antibody,” delivered by subcutaneous injection. On February 2, Immunovant’s stock plunged 42%, and it has been falling ever since. The precipitating factor was an announcement by the company that IMVT-1401 has had its Phase 2b clinical trial, for thyroid eye disease, halted temporarily, due to patients experiencing dangerous rises in their LDL levels. LDLs are the potentially harmful form of cholesterol, which have been connected to cardiovascular disease. Despite the clinical setback, Stiffel’s 5-star analyst Derek Archila reiterated a Buy rating on IMVT shares, along with a $28 price target. This figure suggests a 52% upside potential from current levels. (To watch Archila’s track record, click here) “Interestingly, increases have only been seen in TED patients, and our review of the literature suggests a few things: (1) it's likely this is TED specific given the biology- see below for details, but we don't think similar LDL increases will be seen in other indications outside TED; and (2) other anti-thyroid therapies used in Graves/TED also see similar increases in LDL, which end up being transient. We think IMVT-1401, in away, is replicating this mechanism," the analyst noted. Archila summed up, "While we will need to see additional data from the company to confirm... we don't think this program is dead.” Overall, the Strong Buy analyst consensus view on IMVT would suggest that Wall Street generally agrees with Archila’s assessment. This rating is derived from 8 recent reviews, which include 7 Buys and only a single Hold. The average price target here stands at $40.38, implying ~121% upside for the next 12 months. (See IMVT stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Palantir Declines as 80% of Shares Unlock for Trading

    (Bloomberg) -- Palantir Technologies Inc. slid 6% in the first hour of trading Thursday after a flood of shares became eligible to sell for the first time.The company has amassed a long list of shareholders in the nearly two decades since it was founded. On Thursday, almost all of them have the option to sell as much of their stock as they’d like for the first time.Four-fifths of shares are becoming eligible to trade, the result of an unusual restriction placed on stockholders when Palantir went public. Such lockups are common after initial public offerings but less so for companies that list their shares directly on an exchange, as Palantir did on the New York Stock Exchange in September.Two longtime investors said in interviews that they will hold, but at least one other, billionaire George Soros, has publicly signaled his plans to exit. The shares were down about 8% at the start of trading in New York.The expiration of a lockup is a volatile time for any company but could be especially so for Palantir, which was privately held for an exceptionally long time and which courts a great deal of controversy. Its co-founder and chairman is Peter Thiel, the venture capitalist who backed Donald Trump’s successful bid for the U.S. presidency and became a pariah in Silicon Valley. Palantir, which relocated from the Valley to Denver, works with the military, immigration enforcement and intelligence agencies, all of which draw public scrutiny and howls for surveillance overreach.Soros Fund Management, which revealed in November it began investing in Palantir in 2012 and owned 18.46 million shares, has said it will sell for ethical reasons. The firm said at the time that it had sold all it was able to and “will continue to sell shares as permitted.”“SFM does not approve of Palantir’s business practices,” the firm said in a statement last year. “SFM made this investment at a time when the negative social consequences of big data were less understood. SFM would not make an investment in Palantir today.”Palantir still has plenty of believers. Its tools are used by corporate titans like BP Plc and Merck KGaA as well as governments around the world, nearly a dozen of which are using Palantir to battle Covid-19 and power vaccine distribution. Adit Ventures, which said it holds about $270 million worth of Palantir, told Bloomberg it will sell few, if any, shares on Thursday. Ditto for PHX Financial, which said it holds more than $10 million. Ark Invest has also indicated its support.Palantir’s stock has more than tripled since going public. But the lockup loomed over the company’s quarterly financial report on Tuesday. Despite exceeding analysts’ expectations on revenue and other measures, concerns about growth prospects and the lockup expiration sent the stock falling.Speaking in a prerecorded video shown to investors Tuesday, Chief Executive Officer Alex Karp walks through snowy woods and discusses the perils of technology companies managing for quarterly expectations and “near-term myopism.”Cathie Wood, CEO of Ark Invest, backs that philosophy. “Palantir’s attitude is refreshing,” she said in an interview on CNBC. “It’s exactly how we invest. We want our companies to invest aggressively. We don’t want profits now.”(Updates shares in the first paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Stock market news live updates: Stocks fall after jobless claims data disappoints

    Stock futures edged lower Thursday morning, drifting below record levels.

  • Boeing reminds pilots to monitor planes closely following Indonesia crash-bulletin

    The bulletin, dated Feb. 15., was sent after Indonesia issued a preliminary report into a Jan. 9 Sriwijaya Air crash that killed all 62 people on board a 737-500. It was not explicitly linked to that crash and covers all modern Boeing models but it addresses one of the potential areas of interest for investigators following the accident, pending the discovery of the cockpit voice recorder memory unit. Manufacturers have periodically issued such reminders and Boeing said it regularly communicates with customers on how they can safely and confidently operate their airplanes.

  • Cathie Wood Talks Tesla, Bitcoin, SPACs And More On CNBC: Here Are The Highlights

    Famed investor and ETF manager Cathie Wood joined Scott Wapner and Bob Pisani on the “Halftime Report” on CNBC Wednesday to share opinions on some holdings across her funds. Wood On Tesla: Wood has been a notable bull on Tesla Inc (NASDAQ: TSLA) and it remains the largest holding in the signature Ark Innovation ETF (NYSE: ARKK). “Our confidence in Tesla has grown,” Wood said. The fund manager said no one is modeling the ride-share potential for Tesla when forecasting revenue and price targets. Rideshare could be more profitable for Tesla than electric vehicles. Related Link: 7 Stocks That Fit Cathie Wood’s Big Ideas 2021, Could Be Added To Ark ETFs Wood On Bitcoin: Wood has been bullish on Bitcoin recently hitting on the rise in valuation that could be seen if every S&P 500 company allocated 1% of cash to the cryptocurrency. “We have individuals now who really understand,” Wood said on Gary Gensler, the new U.S. SEC Chair. Gensler taught a class on blockchain and Bitcoin at MIT and understand the technology and valuation, Wood added. The Grayscale Bitcoin Trust (OTC: GBTC) is a popular option for investors in the U.S. to get exposure to Bitcoin as no ETFs are available currently. Wood said the probability of a Bitcoin ETF goes up with new administration understanding cryptocurrency. The fund manager praises companies like Tesla and Square Inc (NYSE: SQ) who are “on the right side of change” by adding Bitcoin and diversifying their cash holdings. Wood On Telemedicine: One of the largest holdings in the Ark ETFs is Teladoc Health (NYSE: TDOC). The telemedicine company is held in the Ark Innovation ETF, Ark Genomic Internet ETF (BATS: ARKG) and Ark Next Generation Internet ETF (NYSE: ARKW). “We had a great opportunity to buy into Teladoc when stay-at-home stocks flattened out,” Wood said. Despite the stock being up 40% in 2021, Wood remains bullish and thinks the company was hurt by public sentiment of the acquisition of Livongo. “This is a beautiful acquisition for Teladoc,"Wood said, adding that the two companies will create a powerhouse of data together. Wood on SPACs: The Ark fund manager has added several SPACs to the portfolio recently, including some that have completed mergers and others like Experience Investment (NASDAQ: EXPC) that are in the merger process. Wood named DraftKings Inc (NASDAQ: DKNG), Skillz (NYSE: SKLZ) and Butterfly Network Inc (NYSE: BFLY) as former SPACs that the Ark funds own. “We are investing in them,” Wood said of SPACs. “We’re being very careful.” Wood said the fund is selective and doesn’t like the incentive structure of some SPACs. The fund manager noted SPACs remain a way for the public markets to invest in some growth sooner than the traditional IPO route. Space ETF: Wood is launching a space ETF under the Ark umbrella of funds soon. Due to a quiet period with the SEC, Wood couldn’t discuss specific space stocks, but was bullish on the overall industry. She called space exploration the right side of change. “We see SpaceX, Blue Origin pushing the envelope,” Wood said of the private companies. She highlighted the work that Elon Musk, Jeff Bezos and Richard Branson have done in the space industry. The costs of launching rockets are coming down dramatically, which could lead to strong growth in the sector, according to Wood. See more from BenzingaClick here for options trades from BenzingaQuantumScape Could Have Breakthrough EV Battery Technology: WedbushOrigin Materials Lands SPAC Deal: What Investors Should Know About Pepsi-, Danone-, Nestle-Backed Company© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.